| Symbol | NBTX |
|---|---|
| Name | NANOBIOTIX S.A. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 60 RUE DE WATTIGNIES, PARIS, 75012, France |
| Telephone | +33 140260470 |
| Fax | — |
| — | |
| Website | https://www.nanobiotix.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | NASDAQ;OTC |
| Auditor | Ernst & Young LLP; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001760854 |
| Description | Nanobiotix SA is a clinical-stage biotechnology company that focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its lead product candidate is NBTXR3, a preclinical research program for cancer immunotherapies. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Nanobiotix S.A. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0002005369-26-000049 <b>Size:</b> 16 KB
Read moreNew Form SCHEDULE 13G/A - Nanobiotix S.A. <b>Filed:</b> 2026-07-29 <b>AccNo:</b> 0001441449-26-000010 <b>Size:</b> 7 KB
Read moreNew Form S-8 - Nanobiotix S.A. <b>Filed:</b> 2026-06-08 <b>AccNo:</b> 0001140361-26-024414 <b>Size:</b> 358 KB
Read moreNANOBIOTIX Announces Full Exercise ofUnderwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
Read more